Real-World Effectiveness of the MiniMed™ 780G Advanced Hybrid Closed-Loop System for People ≥65 Years with Type 1 or Type 2 Diabetes in the United States
Authors' conclusion
In a real-world setting, a U.S. cohort aged ≥65 years using the MM780G system achieved consensus-recommended glycemic targets. Use of ROS enabled more users to achieve an even higher level of glycemic control.
Study context
- Population
- U.S. MM780G advanced hybrid closed-loop system users aged ≥65 years with T1D or T2D; CareLink data as of December 18, 2024
- Participants
- 8,542 vs 2,753
- Exposure
- MM780G users with vs without recommended optimal settings
- Overalln = 8,542
- Recommended optimal settings (ROS)n = 2,753
- Outcome
- Glycemic metrics (mean) in overall cohort
Methodological detailsde-identified CareLink personal data, subanalyses by age (≥75 years) and T1D/T2D
- De-identified CareLink personal data
- Subanalyses by age (≥75 years) and T1D/T2D
Main finding
As reported in the abstract
- TIR 70-180 mg/dL
- 78.4%
- TITR 70-140 mg/dL
- 51.4%
- TBR <70 mg/dL
- 0.9%
- TAR >180 mg/dL
- 20.7%
- TAR >250 mg/dL
- 3.6%
- GMI
- 6.8%
Observational data: associations, not effects.
Further findings
Glycemic metrics in ROS users
- TIR higher in ROS users
- 81.9%
- TITR higher in ROS users
- 55.9%
- TAR180 lower in ROS users
- 17.2%
- TAR250 lower in ROS users
- 2.5%
- P for TIR and TITR
- P < 0.001
- P for TAR180 and TAR250
- P < 0.001
Subgroups: age ≥75 years; T1D vs T2D
- Data trended similarly among those aged ≥75 years
- No differences between T1D and T2D
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Real-World Effectiveness of the MiniMed™ 780G Advanced Hybrid Closed-Loop System for People ≥65 Years with Type 1 or Type 2 Diabetes in the United States. Diabetes Technol Ther. Published 16 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →